美泊利珠单抗改善有至少一次鼻息肉手术史的CRSwNP患者结局
SYNAPSE研究的事后分析按既往鼻息肉手术次数(1次 vs >1次)分层,评估美泊利珠单抗每4周皮下注射52周的疗效。结果显示,在两个亚组中,美泊利珠单抗均显著改善鼻息肉评分、鼻塞、嗅觉丧失、整体症状VAS和SNOT-22;在仅有1次手术史的患者中,还显著降低重复手术和口服激素的风险。提示在首次手术后尽早启用可能获益更大。
要点
- 美泊利珠单抗在≥1次鼻息肉手术史的CRSwNP患者中改善多项结局。
- 仅有1次手术史的患者中,美泊利珠单抗显著降低重复手术和OCS使用风险。
- 手术次数>1次的患者同样获益,但可能不如1次手术史者明显。
核心结论
- 美泊利珠单抗改善有1次或多次既往手术的CRSwNP患者结局,但在仅一次手术后启用可能获益更大。
研究设计与样本
- SYNAPSE III期研究(GSK ID:205687; NCT0308579)的事后分析,按既往鼻息肉手术次数(1次 vs >1次)分层。
- 患者随机接受美泊利珠单抗或安慰剂每4周一次,联合标准治疗,治疗52周。
- 1次手术史亚组189例(美泊利珠单抗108例;安慰剂81例);>1次手术史亚组218例(98例;120例)。
主要发现
- 两个亚组中,美泊利珠单抗较安慰剂均显著改善鼻息肉评分、鼻塞VAS、嗅觉丧失VAS、整体症状VAS和SNOT-22的平均变化。
- 在仅有1次手术史的患者中,美泊利珠单抗较安慰剂显著降低重复手术风险和需要OCS的风险。
临床怎么用
- 对于有至少一次鼻息肉手术史的CRSwNP患者,可考虑使用美泊利珠单抗以减少复发和重复手术风险。
- 在首次手术后尽早启用美泊利珠单抗可能带来更大获益。
局限性
- 为事后分析,亚组样本量有限,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) often undergo multiple nasal surgeries. The Phase III SYNAPSE study (GSK ID:205687; NCT0308579) demonstrated that mepolizumab reduces the need for repeat surgery. We explored whether outcomes differed based on the number of prior surgeries. METHODOLOGY: This post hoc analysis of SYNAPSE stratified patients by history of 1 or more than 1 prior surgery. Patients were randomised to receive mepolizumab or placebo every 4 weeks, alongside standard of care, for 52 weeks. Outcomes included change from baseline in endoscopic nasal polyp (NP) score, visual analogue scale (VAS) scores for nasal obstruction, loss of smell and overall symptoms, Sino-Nasal Outcome Test-22 (SNOT-22), and time to repeat surgery and/or oral corticosteroid (OCS) use. RESULTS: 189 patients had 1 prior surgery (108 mepolizumab; 81 placebo) and 218 had more than 1 prior surgery (98; 120). In both subgroups, mepolizumab significantly improved mean changes versus placebo in NP, nasal obstruction, loss of smell VAS, overall symptom VAS, and SNOT-22. Significant reductions in risk of repeat surgery and requiring OCS were observed with mepolizumab versus placebo in patients with 1 prior surgery. CONCLUSIONS: Mepolizumab improves outcomes in patients with CRSwNP with one or multiple prior surgeries; however, may offer greater benefit when initiated after a single surgery.
引用
- Han JK, Mullol J, Wagenmann M, et al. Mepolizumab improves outcomes in patients with CRSwNP with one or more prior nasal polyp surgeries. Rhinology. 2026. PMID: 42206465. doi:10.4193/Rhin25.599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。